XML 30 R13.htm IDEA: XBRL DOCUMENT
v3.19.1

Fair Value Measurements | 12 Months Ended
--- | ---
Dec. 31, 2018
Fair Value Disclosures [Abstract] |
Fair Value Measurements | Fair Value Measurements The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):
Description | December 31, 2018 |  | Quoted Prices In Active Markets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Unobservable Inputs (Level 3)
Assets: |  |  |  |  |  |  |
Cash equivalents | $ | 5,195 |  |  | $ | 5,195 |  |  | $ | — |  |  | $ | — |
Total assets measured and recorded at fair value | $ | 5,195 |  |  | $ | 5,195 |  |  | $ | — |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |
Warrants potentially settleable in cash | $ | 1,013 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,013 |
Contingent consideration | 4,326 |  |  | — |  |  | — |  |  | 4,326 |
Total liabilities measured and recorded at fair value | $ | 5,339 |  |  | $ | — |  |  | $ | — |  |  | $ | 5,339 |
Description | December 31, 2017 |  | Quoted Prices In Active Markets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Unobservable Inputs (Level 3)
Assets: |  |  |  |  |  |  |
Cash equivalents | $ | 1,662 |  |  | $ | 1,662 |  |  | $ | — |  |  | $ | — |
Restricted cash equivalents | 10,245 |  |  | 10,245 |  |  | — |  |  | — |
Total assets measured and recorded at fair value | $ | 11,907 |  |  | $ | 11,907 |  |  | $ | — |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |
Warrants potentially settleable in cash | $ | 1,309 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,309 |
Contingent consideration | 1,294 |  |  | — |  |  | — |  |  | 1,294 |
Total liabilities measured and recorded at fair value | $ | 2,603 |  |  | $ | — |  |  | $ | — |  |  | $ | 2,603 |
The Company did not transfer any financial instruments into or out of Level 3 classification during the years ended December 31, 2018 and 2017. See Note 12 for a reconciliation of the changes in the fair value of the warrant liability for the years ended December 31, 2018. A reconciliation of the change in the fair value of the contingent consideration liability for the years ended December 31, 2018 and 2017 is as follows (in thousands):
| Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Contingent consideration, January 1, 2017 | $ | — |
Contingent consideration acquired as part of the Merger | 1,294 |
Contingent consideration, December 31, 2017 | $ | 1,294 |
Change in the estimated fair value of the contingent consideration | 3,032 |
Contingent consideration, December 31, 2018 | $ | 4,326 |
The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena’s acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to $32.0 million based on the achievement of certain development and commercial milestones relating to NPS. The contingent consideration is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it has first obtained approval of its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The change in the estimated fair value of the contingent consideration during the year ended December 31, 2018 reflects an adjusted probability and timeline for the potential approval of NPS associated with the positive interim data in the triple-negative breast cancer cohort from the prospective, randomized, single-blinded, controlled Phase 2b investigator-sponsored clinical trial of trastuzumab (Herceptin®) +/- NPS in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences that was announced on April 2, 2018.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References No definition available. + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration